source
- Pfizer signs $2.6 billion deal with China's Starna to acquire in vivo CAR-T programs for autoimmune diseasesPfizer announced a $2.6 billion agreement with Chinese biotech Starna Therapeutics to obtain rights to three preclinical in vivo CAR-T candidates aimed at autoimmune diseases. The deal includes a…
- White House pulls nomination for FDA nominee OvertonThe sudden end of Heidi Overton’s candidacy likely ensures a Democrat-controlled Congress will choose the FDA’s next leader — but shouldn’t disrupt the agency, analysts say.BioPharma Dive · 3h ago↗ source